{"id":"miglustat-zavesca","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Diarrhea"},{"rate":"20-40","effect":"Weight loss"},{"rate":"10-20","effect":"Tremor"},{"rate":"10-15","effect":"Peripheral neuropathy"},{"rate":"10-20","effect":"Abdominal pain"},{"rate":"10-15","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1029","moleculeType":"Small molecule","molecularWeight":"219.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Miglustat is a glucosylceramide synthase inhibitor that blocks the first committed step in glycosphingolipid synthesis. By reducing glucosylceramide accumulation, it slows the progression of lysosomal storage diseases caused by deficient glucocerebrosidase or galactocerebrosidase activity. This substrate reduction therapy approach helps restore cellular function in affected tissues.","oneSentence":"Miglustat inhibits glucosylceramide synthase, reducing the accumulation of glucosylceramide and related glycosphingolipids in cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:14.929Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gaucher disease type 1 (non-neuronopathic)"},{"name":"Niemann-Pick disease type C"},{"name":"Progressive myoclonic epilepsy type 2 (Lafora disease)"}]},"trialDetails":[{"nctId":"NCT07399704","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease","status":"RECRUITING","sponsor":"Azafaros A.G.","startDate":"2026-02-04","conditions":"GM2 Gangliosidosis, Niemann-Pick Type C Disease","enrollment":21},{"nctId":"NCT06121011","phase":"","title":"A Global Prospective Observational Registry of Patients With Pompe Disease","status":"RECRUITING","sponsor":"Amicus Therapeutics","startDate":"2024-02-16","conditions":"Pompe Disease","enrollment":500},{"nctId":"NCT04138277","phase":"PHASE3","title":"A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)","status":"COMPLETED","sponsor":"Amicus Therapeutics","startDate":"2019-12-18","conditions":"Pompe Disease (Late-onset)","enrollment":119},{"nctId":"NCT04808505","phase":"PHASE3","title":"A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18","status":"RECRUITING","sponsor":"Amicus Therapeutics","startDate":"2023-07-18","conditions":"Glycogen Storage Disease Type II Infantile Onset","enrollment":36},{"nctId":"NCT02325362","phase":"PHASE2, PHASE3","title":"Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-03-17","conditions":"Cystic Fibrosis","enrollment":16},{"nctId":"NCT03911505","phase":"PHASE3","title":"ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amicus Therapeutics","startDate":"2020-02-13","conditions":"Pompe Disease (Late-onset)","enrollment":21},{"nctId":"NCT02675465","phase":"PHASE1, PHASE2","title":"First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221","status":"COMPLETED","sponsor":"Amicus Therapeutics","startDate":"2016-04","conditions":"Pompe Disease","enrollment":29},{"nctId":"NCT03822013","phase":"PHASE3","title":"Effects of Miglustat Therapy on Infantile Type of Sandhoff and Taysachs Diseases (EMTISTD)","status":"TERMINATED","sponsor":"Tehran University of Medical Sciences","startDate":"2019-01-14","conditions":"GM2 Gangliosidosis, Supportive Care","enrollment":30},{"nctId":"NCT03729362","phase":"PHASE3","title":"A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease","status":"COMPLETED","sponsor":"Amicus Therapeutics","startDate":"2018-12-04","conditions":"Pompe Disease (Late-onset)","enrollment":125},{"nctId":"NCT04327973","phase":"","title":"Expanded Access for ATB200/AT2221 for the Treatment of IOPD","status":"AVAILABLE","sponsor":"Amicus Therapeutics","startDate":"","conditions":"Pompe Disease Infantile-Onset","enrollment":""},{"nctId":"NCT05174039","phase":"PHASE1, PHASE2","title":"An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease","status":"COMPLETED","sponsor":"Beyond Batten Disease Foundation","startDate":"2022-03-10","conditions":"Batten Disease","enrollment":6},{"nctId":"NCT03910621","phase":"PHASE4","title":"Safety and Efficacy of Miglustat in Chinese NPC Patients","status":"COMPLETED","sponsor":"Actelion","startDate":"2020-04-02","conditions":"Niemann-Pick Disease, Type C","enrollment":17},{"nctId":"NCT00517153","phase":"PHASE2","title":"Miglustat in Niemann-Pick Type C Disease","status":"COMPLETED","sponsor":"Actelion","startDate":"2002-01","conditions":"Niemann-Pick Type C Disease","enrollment":29},{"nctId":"NCT00319046","phase":"PHASE3","title":"Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"Actelion","startDate":"2006-02-01","conditions":"Gaucher Disease Type 1","enrollment":42},{"nctId":"NCT04768166","phase":"PHASE2","title":"Testing Miglustat Administration in Subjects With Spastic Paraplegia 11","status":"COMPLETED","sponsor":"IRCCS Fondazione Stella Maris","startDate":"2021-06-15","conditions":"Hereditary Spastic Paraparesis","enrollment":10},{"nctId":"NCT02030015","phase":"PHASE4","title":"Synergistic Enteral Regimen for Treatment of the Gangliosidoses","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2015-12-22","conditions":"GM1 Gangliosidoses, GM2 Gangliosidoses, Tay-Sachs Disease","enrollment":16},{"nctId":"NCT02520934","phase":"NA","title":"Miglustat on Gaucher Disease Type IIIB","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2015-07","conditions":"Gaucher Disease","enrollment":19},{"nctId":"NCT02185651","phase":"PHASE1","title":"A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction","status":"TERMINATED","sponsor":"University of Florida","startDate":"2016-10","conditions":"Pompe Disease, Hypersensitivity Reaction","enrollment":2},{"nctId":"NCT01451879","phase":"","title":"Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies","status":"COMPLETED","sponsor":"University of Florida","startDate":"2008-10","conditions":"Pompe Disease","enrollment":11},{"nctId":"NCT00316498","phase":"PHASE1","title":"Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2002-10-17","conditions":"Niemann Pick Diseases","enrollment":30},{"nctId":"NCT00041535","phase":"PHASE2","title":"OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2002-07-05","conditions":"Gaucher Disease","enrollment":30},{"nctId":"NCT00418847","phase":"PHASE2","title":"Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2004-07","conditions":"Gangliosidoses GM2","enrollment":5},{"nctId":"NCT01822028","phase":"PHASE1","title":"Two Period / Two Treatment Cross-over to Assess the Effect of Florastor® on Gastrointestinal Tolerability, Safety, and PK in Healthy Subjects Receiving Zavesca®","status":"COMPLETED","sponsor":"Actelion","startDate":"2013-03","conditions":"Diarrhea","enrollment":42},{"nctId":"NCT00742092","phase":"PHASE2","title":"Miglustat in Cystic Fibrosis","status":"COMPLETED","sponsor":"Actelion","startDate":"2008-08","conditions":"Cystic Fibrosis","enrollment":11},{"nctId":"NCT01760564","phase":"PHASE3","title":"Application of Miglustat in Patients With Niemann-Pick Type C","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2008-01","conditions":"Niemann-Pick Disease Type C","enrollment":5},{"nctId":"NCT00945347","phase":"PHASE2","title":"Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ?","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2009-07","conditions":"Cystic Fibrosis","enrollment":10},{"nctId":"NCT00537602","phase":"PHASE2","title":"Miglustat / OGT 918 in the Treatment of Cystic Fibrosis","status":"TERMINATED","sponsor":"Actelion","startDate":"2007-11","conditions":"Cystic Fibrosis","enrollment":6},{"nctId":"NCT00194649","phase":"PHASE4","title":"Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2005-06","conditions":"Contraception","enrollment":8},{"nctId":"NCT00672022","phase":"PHASE3","title":"Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses","status":"COMPLETED","sponsor":"Children's National Research Institute","startDate":"2004-07","conditions":"GM2 Gangliosidoses, Tay-Sachs, Sandhoff Disease","enrollment":10},{"nctId":"NCT00002079","phase":"PHASE2","title":"Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)","status":"COMPLETED","sponsor":"G D Searle","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00001993","phase":"PHASE2","title":"Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3","status":"COMPLETED","sponsor":"G D Searle","startDate":"","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00000692","phase":"PHASE1","title":"Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex","status":"COMPLETED","sponsor":"G D Searle","startDate":"","conditions":"HIV Infections","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zavseca"],"phase":"marketed","status":"active","brandName":"Miglustat (Zavesca)","genericName":"Miglustat (Zavesca)","companyName":"University of Washington","companyId":"university-of-washington","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Miglustat inhibits glucosylceramide synthase, reducing the accumulation of glucosylceramide and related glycosphingolipids in cells. Used for Gaucher disease type 1 (substrate reduction therapy), Niemann-Pick type C disease, Progressive myoclonic epilepsy type 2 (Lafora disease) — investigational.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}